| payload |
{"artifact_id":"artf_thesis_c7356296d3 {"artifact_id":"artf_thesis_c7356296d396cb2c","evidence_event_ids":["evt_15da6034e032","evt_7df7bc422d50"],"kind":"opportunity_thesis","meta":{"confidence":0.3853,"lane":"monitor","morning_holdback":false,"rank_score":0.3853,"theme_keys":[],"urgency_reason":"not_urgent","urgent":false},"output_json":{"artifact_kind_detail":"research_thesis","catalysts":[],"confidence":0.3853,"decision_reason_codes":["research_thesis"],"headline":"Form 4 for Xilio Therapeutics, Inc. (XLO) was filed on 2026-04-16 and discloses a stock option grant to Cheryl R. Blanchard with vesting on April 15 of 2027, 2028, and 2029 (subject to continued service).","investigation_questions":["What changed vs prior known state is not provided in the signal; no prior holdings/transactions are included to compare against.","The filing text excerpt does not explicitly state whether this is the only reported transaction in the Form 4 beyond the single ownership..."],"portfolio_fit":{"applied":false,"boost":0.0,"exit_risk_flagged":false,"hedge_suggested":null,"matched_holdings":[],"matched_watchlist":[],"stub_version":"v1","why_you":""},"related_tickers":["XLO"],"risk_level":"medium","theme_keys":[],"thesis":"Form 4 \u00b7 Xilio Therapeutics, Inc. \u00b7 Filed 20260416; SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4); Issuer: Xilio Therapeutics, Inc. (XLO) \u2014 Signal convergence: Form 4 for Xilio Therapeutics, Inc. (XLO) was filed on 2026-04-16 and discloses a stock option grant to Cheryl R. Blanchard with vesting on April 15 of 2027, 2028, and 2029 (subject to continued service). [neutral]"},"ready_at":"2026-04-17T03:41:54.580555+00:00","status":"ready","summary":"Form 4 \u00b7 Xilio Therapeutics, Inc. \u00b7 Filed 20260416; SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4); Issuer: Xilio Therapeutics, Inc. (XLO) \u2014 Signal convergence: Form 4 for Xilio Therapeutics, Inc. (XLO) was filed on 2026-04-16 and discloses a stock option grant to Cheryl R. Blanchard with vesting on April 15 of 2027, 2028, and 2029 (subject to continued s","title":"[THESIS] XLO \u2014 Form 4 for Xilio Therapeutics, Inc. (XLO) was filed on 2026-04-16 and discloses a stock option grant to Cheryl R. Blanchard with vesting on April 15 of 2027, 2028, and 2029 (subject to","updated_at":"2026-04-17T03:41:54.580555+00:00"}... |